• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.

作者信息

Quan Joshua, Ma Christopher, Panaccione Remo, Hracs Lindsay, Sharifi Nastaran, Herauf Michelle, Makovinović Ante, Coward Stephanie, Windsor Joseph W, Caplan Léa, Ingram Richard J M, Kanji Jamil N, Tipples Graham, Holodinsky Jessalyn K, Bernstein Charles N, Mahoney Douglas J, Bernatsky Sasha, Benchimol Eric I, Kaplan Gilaad G

机构信息

Inflammatory Bowel Disease Clinic, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Alberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada.

出版信息

Gut. 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23.

DOI:10.1136/gutjnl-2022-327440
PMID:35606090
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10086278/
Abstract
摘要

相似文献

1
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.炎症性肠病患者对三剂严重急性呼吸综合征冠状病毒2疫苗接种的血清学反应。
Gut. 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23.
2
Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.炎症性肠病患者接种 SARS-CoV-2 疫苗后抗体生成受损：一项泛希腊注册研究的结果。
Inflamm Bowel Dis. 2023 Feb 1;29(2):228-237. doi: 10.1093/ibd/izac068.
3
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.肠道微生物组和代谢组与免疫抑制性炎症性肠病患者 COVID-19 疫苗诱导的抗体反应减弱有关。
EBioMedicine. 2023 Feb;88:104430. doi: 10.1016/j.ebiom.2022.104430. Epub 2023 Jan 10.
4
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.炎症性肠病患者的新型冠状病毒2型疫苗接种：一项国际共识会议的建议
Gut. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20.
5
Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients.儿童炎症性肠病患者感染或接种SARS-CoV-2后的血清转化
Inflamm Bowel Dis. 2021 Oct 20;27(11):1862-1864. doi: 10.1093/ibd/izab194.
6
Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?免疫抑制治疗的炎症性肠病患者接种 SARS-CoV-2 疫苗后的体液免疫原性：我们是否应该优先考虑额外加强注射？
Inflamm Bowel Dis. 2023 Feb 1;29(2):268-273. doi: 10.1093/ibd/izac187.
7
Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.德国一家三级医院的单中心队列研究：炎症性肠病患者对 SARS-CoV-2 疫苗接种的抗体反应。
Dig Dis. 2022;40(6):719-727. doi: 10.1159/000521343. Epub 2021 Dec 10.
8
Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.炎症性肠病患者对前四剂严重急性呼吸综合征冠状病毒2疫苗的血清学反应。
Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1077-1079. doi: 10.1016/S2468-1253(22)00340-5. Epub 2022 Oct 26.
9
SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: correspondence.炎症性肠病患者使用不同生物制剂时的 SARS-CoV-2 疫苗接种：通信。
Rev Esp Enferm Dig. 2023 Sep;115(9):531. doi: 10.17235/reed.2023.9347/2022.
10
COVID-19 and Inflammatory Bowel Disease.新型冠状病毒肺炎与炎症性肠病。
Gastroenterol Clin North Am. 2023 Mar;52(1):103-113. doi: 10.1016/j.gtc.2022.10.005. Epub 2022 Oct 31.

引用本文的文献

1
Durability of Antibody Responses to SARS-CoV-2 Vaccination over 12 Months in Pediatric Inflammatory Bowel Disease.儿童炎症性肠病中SARS-CoV-2疫苗接种后12个月抗体反应的持久性
Vaccines (Basel). 2025 May 22;13(6):549. doi: 10.3390/vaccines13060549.
2
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.新型冠状病毒肺炎与炎症性肠病实用最新进展：新型冠状病毒肺炎疾病风险及疫苗安全性与有效性
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):88-97.
3
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.

本文引用的文献

1
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.英夫利昔单抗和维得利珠单抗治疗的炎症性肠病患者接种两剂 SARS-CoV-2 疫苗后的抗体衰减、T 细胞免疫和突破性感染。
Nat Commun. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z.
2
Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.加拿大安大略省炎症性肠病患者中 SARS-CoV-2 疫苗第三剂的接种情况。
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):288-289. doi: 10.1016/S2468-1253(22)00054-1. Epub 2022 Feb 23.
3
接受抗肿瘤坏死因子治疗的炎症性肠病患者接种3剂mRNA新冠疫苗后产生更高且持续的细胞介导免疫反应。
Clin Transl Gastroenterol. 2024 Apr 1;15(4):e00688. doi: 10.14309/ctg.0000000000000688.
4
Immunization of children with inflammatory bowel disease against SARS-CoV-19 infection: A prospective single centre cohort study.炎症性肠病患儿接种新冠病毒疫苗预防SARS-CoV-19感染：一项前瞻性单中心队列研究。
Vaccine X. 2023 Aug 19;15:100374. doi: 10.1016/j.jvacx.2023.100374. eCollection 2023 Dec.
5
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects.免疫抑制的炎症性肠病患者第三次接种严重急性呼吸综合征冠状病毒2疫苗后的体液免疫：与健康对照者的比较
Vaccines (Basel). 2023 Aug 24;11(9):1411. doi: 10.3390/vaccines11091411.
6
The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD.2023年炎症性肠病对加拿大的影响：COVID-19与炎症性肠病
J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S76-S82. doi: 10.1093/jcag/gwad019. eCollection 2023 Sep.
7
COVID-19 vaccination in adults with inflammatory bowel disease.炎症性肠病成年患者的新冠病毒疫苗接种
Therap Adv Gastroenterol. 2023 May 22;16:17562848231173130. doi: 10.1177/17562848231173130. eCollection 2023.
8
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.肠道炎症中 SARS-CoV-2 免疫的全身和 T 细胞相关反应（STAR SIGN 研究）：生物制剂对 mRNA 疫苗第三剂预防 SARS-CoV-2 效果的影响。
Aliment Pharmacol Ther. 2023 Jan;57(1):103-116. doi: 10.1111/apt.17264. Epub 2022 Oct 28.
9
Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.炎症性肠病患者对前四剂严重急性呼吸综合征冠状病毒2疫苗的血清学反应。
Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1077-1079. doi: 10.1016/S2468-1253(22)00340-5. Epub 2022 Oct 26.
10
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.COVID-19 疫苗接种后第三剂后炎症性肠病免疫抑制患者的抗体和 T 细胞反应（VIP）：一项多中心、前瞻性、病例对照研究。
Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9.
Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
COVID-19 疫苗在 9447 例 IBD 患者中的有效性和持久性：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2022 Jul;20(7):1456-1479.e18. doi: 10.1016/j.cgh.2022.02.030. Epub 2022 Feb 19.
4
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases.炎症性肠病患者对 SARS-CoV-2 疫苗加强剂量的强烈反应。
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1881-1883.e1. doi: 10.1016/j.cgh.2022.01.056. Epub 2022 Feb 9.
5
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations.加拿大克罗恩病与结肠炎协会《2021年加拿大COVID-19与炎症性肠病的影响：COVID-19疫苗——生物学、现有证据及建议》
J Can Assoc Gastroenterol. 2021 Nov 5;4(Suppl 2):S54-S60. doi: 10.1093/jcag/gwab033. eCollection 2021 Dec.
6
Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis.免疫介导的炎症性疾病患者对 2019 年冠状病毒病（COVID-19）疫苗接种的血清学反应：系统评价和荟萃分析。
Gastroenterology. 2022 Jan;162(1):88-108.e9. doi: 10.1053/j.gastro.2021.09.055. Epub 2021 Sep 29.
7
Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.炎症性肠病患者对新冠病毒2的抗体反应随时间减弱：一项血清学监测队列研究。
Gut. 2022 Jun;71(6):1229-1231. doi: 10.1136/gutjnl-2021-325238. Epub 2021 Aug 2.
8
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.英夫利昔单抗与 IBD 患者对 BNT162b2 和 ChAdOx1 nCoV-19 SARS-CoV-2 疫苗的免疫原性降低有关。
Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.